机构：[1]Shanghai Gen Hosp, Shanghai, Peoples R China[2]Origimed, Pathol, Shanghai, Peoples R China[3]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院[4]Shandong Univ, Shandong Prov Hosp, Jinan, Shandong, Peoples R China[5]Xingtai Peoples Hosp, Xingtai, Peoples R China[6]Qilu Hosp, Qingdao Branch, Qingdao, Shandong, Peoples R China[7]Origimed, Shanghai, Peoples R China
第一作者机构：[1]Shanghai Gen Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Ben S.,Pan X.,Wen S.,et al.More than 40% of Locally Advanced or Metastatic NSCLC Patients Without EGFR/ALK Alterations Have PD-L1 TPS >= 1% in China[J].JOURNAL OF THORACIC ONCOLOGY.2019,14(10):S509-S509.doi:10.1016/j.jtho.2019.08.1062.
APA：
Ben, S.,Pan, X.,Wen, S.,Jiang, Y.,Guo, J....&Zhang, S..(2019).More than 40% of Locally Advanced or Metastatic NSCLC Patients Without EGFR/ALK Alterations Have PD-L1 TPS >= 1% in China.JOURNAL OF THORACIC ONCOLOGY,14,(10)
MLA：
Ben, S.,et al."More than 40% of Locally Advanced or Metastatic NSCLC Patients Without EGFR/ALK Alterations Have PD-L1 TPS >= 1% in China".JOURNAL OF THORACIC ONCOLOGY 14..10(2019):S509-S509
医学